Consolidative Surgery for Advanced Upper Urinary Tract Urothelial Carcinoma After Enfortumab Vedotin and/or Immune Checkpoint Inhibitors
European Urology Focus · 2026-09 · 12 (4) · 805-809
DOI: 10.1016/j.euf.2026.03.006 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Urology Focus, 2026-09. Verfasst von Satoru Taguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Electronic address: satorutaguchi33@gmail.com. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Transitional Cell, Ureteral Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Upper urinary tract urothelial carcinoma (UTUC) is a rare malignancy with a poor prognosis in advanced disease. With the advent of novel systemic therapies, including enfortumab vedotin (EV) and immune checkpoint inhibitors (ICIs), deep and durable responses can now be achieved, potentially enabling consolidative surgery with curative intent. However, evidence supporting this approach in advanced UTUC remains scarce. We report a case series of five patients with advanced UTUC who underwent consolidative surgery after EV and/or ICI therapy. All patients achieved sufficient disease control with systemic therapy to allow surgical consolidation, including cases in which the primary tumor showed regrowth and metastatic lesions had nearly or completely resolved during systemic therapy. Consolidative surgery was successfully performed with negative surgical margins in all cases. At a median follow-up of 12 (6-30) mo after surgery, all five patients remained alive, with no evidence of disease, and three patients achieved complete discontinuation of systemic therapy. These findings suggest that consolidative surgery after modern systemic therapy, including EV and/or ICIs, may provide durable disease control and treatment-free survival in selected patients with advanced UTUC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan. Electronic address: satorutaguchi33@gmail.com.
- Department of Urology, Ome Municipal General Hospital, Ome, Tokyo, Japan.
- Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Zitieren
APA
Taguchi, S., Shimizu, M., Tsuru, I., Kamei, J., Kakutani, S., Mori, Y., Murata, T., Yamada, Y., & Kume, H. (2026). Consolidative Surgery for Advanced Upper Urinary Tract Urothelial Carcinoma After Enfortumab Vedotin and/or Immune Checkpoint Inhibitors. European Urology Focus, 12(4), 805-809. https://doi.org/10.1016/j.euf.2026.03.006
Vancouver
Taguchi S, Shimizu M, Tsuru I, Kamei J, Kakutani S, Mori Y, et al. Consolidative Surgery for Advanced Upper Urinary Tract Urothelial Carcinoma After Enfortumab Vedotin and/or Immune Checkpoint Inhibitors. European Urology Focus. 2026;12(4):805-809. doi:10.1016/j.euf.2026.03.006
BibTeX
@article{Taguchi2026,
author = {Taguchi, Satoru and Shimizu, Michinori and Tsuru, Ibuki and Kamei, Jun and Kakutani, Shigenori and Mori, Yoichi and Murata, Takashi and Yamada, Yuta and Kume, Haruki},
title = {Consolidative Surgery for Advanced Upper Urinary Tract Urothelial Carcinoma After Enfortumab Vedotin and/or Immune Checkpoint Inhibitors},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {4},
pages = {805--809},
doi = {10.1016/j.euf.2026.03.006}
}
EUVIMED